American journal of respiratory and critical care medicine
-
Am. J. Respir. Crit. Care Med. · Jun 2013
Randomized Controlled TrialRandomized placebo-controlled trial to evaluate chronic dosing effects of propranolol in asthma.
Unblinded studies have shown improvements in airway hyperresponsiveness with chronic nadolol in steroid-naive patients with asthma. ⋯ This is the first placebo-controlled study to assess the effects of chronic nonselective β-blockade in asthma, showing no significant effect of propranolol compared with placebo on either methacholine or histamine airway hyperresponsiveness and no change in ACQ or AQLQ. Clinical trial registered with www.clinicaltrials.gov (NCT01074853).
-
Am. J. Respir. Crit. Care Med. · Jun 2013
Randomized Controlled TrialDoes the respiratory system limit exercise in mild chronic obstructive pulmonary disease?
It is not known if abnormal dynamic respiratory mechanics actually limit exercise in patients with mild chronic obstructive pulmonary disease (COPD). We reasoned that failure to increase peak ventilation and Vt in response to dead space (DS) loading during exercise would indicate true ventilatory limitation to exercise in mild COPD. ⋯ These results show that the respiratory system reached or approached its physiologic limit in mild COPD at a lower peak work rate and ventilation than in healthy participants. Clinical trial registered with www.clinicaltrials.gov (NCT 00975403).
-
Am. J. Respir. Crit. Care Med. · Jun 2013
Randomized Controlled Trial Multicenter Study Comparative StudyWean earlier and automatically with new technology (the WEAN study). A multicenter, pilot randomized controlled trial.
Automated weaning has not been compared with a paper-based weaning protocol in North America. ⋯ Compared with a standardized protocol, automated weaning was associated with promising outcomes that warrant further investigation. Minor protocol modifications may increase compliance, facilitate recruitment, and enhance feasibility. Clinical trial registered with www.controlled-trials.com (ISRCTN43760151).
-
Am. J. Respir. Crit. Care Med. · Jun 2013
Randomized Controlled Trial Comparative StudyModerately preterm children have more respiratory problems during their first 5 years of life than children born full term.
Pulmonary outcomes of moderate-preterm children (MP) are unknown. ⋯ MP have more respiratory symptoms than FT during early childhood. Factors associated with respiratory symptoms at school age are early respiratory problems, family history of asthma, higher social class, and passive smoking.
-
Am. J. Respir. Crit. Care Med. · Jun 2013
Randomized Controlled Trial Multicenter StudyEfficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation.
Ivacaftor (VX-770), a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, has been shown to improve lung function, pulmonary exacerbation rate, respiratory symptoms, and weight gain compared with placebo in patients with cystic fibrosis aged 12 years or older with a G551D-CFTR mutation. ⋯ In patients who are younger and healthier than those in previously studied populations, ivacaftor demonstrated a significant improvement in pulmonary function, weight, and CFTR activity compared with placebo. Clinical trial registered with www.clinicaltrials.gov (NCT00909727).